QPPV.COM KNOWLEDGE ASSESSMENT

Deoxycholic Acid Injection (Kybella): Development, Safety Evolution and Pharmacovigilance

Test your understanding of the concepts covered by Deoxycholic Acid Injection (Kybella): Development, Safety Evolution and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which governance record would best support a traceable signal-management decision concerning persistent lesions?

A summary of the final decision alone, without the data cut or case definition. The assessed question, data cut, search strategy, case definition, deduplication, literature, local label comparison, limitations, rationale and follow-up owner. A list of all reports, with no explanation of how duplicates were handled. A statement that the US label applies globally, with no local assessment.

Question 2 of 10 A patient has pre-existing dysphagia and is being considered for treatment. Which statement best reflects the label information described?

Dysphagia is relevant only if injections are given outside the submental region. Dysphagia is a reason for particular caution because treatment may worsen it. Pre-existing dysphagia confirms that the product will cause nerve injury. The label identifies dysphagia only as a postmarketing coding term, not a clinical risk.

Question 3 of 10 Which interpretation of the development and commercial history is most accurate?

Bayer retained global rights through the 2015 US approval and launch. Kythera developed ATX-101, later consolidated ex-US and Canada rights from Bayer, and was subsequently acquired by Allergan, which later became part of AbbVie. AbbVie discovered deoxycholic acid and initiated the original ATX-101 studies. The ownership changes themselves altered the authorised indication.

Question 4 of 10 Why should the common local reactions observed in pivotal trials not be treated as a complete description of the product's lifetime safety profile?

The pivotal trials included only placebo recipients. Local reactions in trials cannot be considered safety data. The trials were not large or long enough to characterise every rare, delayed or use-dependent complication after broader commercial use. Any event first reported after approval must be unrelated to the product.

Question 5 of 10 Phase I data showed that mean plasma deoxycholic acid rose shortly after treatment and returned to endogenous baseline on average by 24 hours. What conclusion is best supported?

The treatment cannot cause clinically meaningful local tissue injury. The findings support a predominantly local treatment concept but do not establish safety at unstudied sites. The short systemic exposure proves that repeated injections cannot cause adverse reactions. The product should be treated as a systemic weight-management medicine.

Question 6 of 10 A clinic identifies the product only as 'deoxycholic acid injection'; the package and manufacturer are unavailable. Which action best supports reliable assessment?

Assume it was Kybella because the reported active ingredient is the same. Exclude the case because product identity cannot be confirmed immediately. Record the product identity as uncertain and seek brand, manufacturer, source, package or lot details where possible. Combine it with all Kybella cases without retaining product uncertainty.

Question 7 of 10 What is the most accurate interpretation of deoxycholic acid's biological history in the development of ATX-101?

ATX-101 introduced a newly discovered molecule with no prior human biological role. ATX-101 adapted the local cytolytic properties of an endogenous secondary bile acid into a standardised injectable formulation. ATX-101 was developed as a systemic replacement for naturally occurring bile acids. ATX-101's development depended on proving that deoxycholic acid has no effects on cell membranes.

Question 8 of 10 Which description best explains the product's intended pharmacological action in its authorised setting?

It produces systemic appetite suppression that reduces total body fat. It blocks bile-acid synthesis throughout the body to alter lipid metabolism. It dissolves adipose tissue selectively wherever it is injected, regardless of anatomy. It physically disrupts cell membranes and causes local cell lysis in injected submental fat.

Question 9 of 10 Which statement best characterises the relationship between the 2015 approval review and the 2026 postmarketing label update?

The later action can reflect risks identified through broader postmarketing use that were not adequately characterised in the original trial programme. The 2026 action proves that the 2015 benefit–risk assessment was necessarily incorrect. The 2015 review established that use outside the studied region was safe. The 2026 update removes the need to assess individual cases for product identity and causality.

Question 10 of 10 What does FDA's 2026 label action most directly demonstrate?

That every postmarketing report reviewed met a definitive causal standard. That the original pivotal trial results were invalid. That all administration outside the submental region produces serious harm. That later postmarketing evidence can lead to clearer risk communication even when case counts do not establish incidence.

QPPV.com

Deoxycholic Acid Injection (Kybella): Development, Safety Evolution and Pharmacovigilance

Cookie Settings